# A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants

> **NCT02882009** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 48 (estimated)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** Gantenerumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02882009
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-31
- **Primary completion:** 2017-03-22
- **Final completion:** 2017-03-22
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2019-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02882009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02882009, "A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02882009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*